The main purpose of this study is to evaluate the safety of a study drug known as LY2835219 in combination with different standard therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, or trastuzumab) for breast cancer that has spread to other parts of the body. The combination of LY2835219 plus trastuzumab was added as a study treatment (by protocol amendment).
Find Clinical Trials
To find clinical trials that focus on targeted therapies, use the pulldown menus below or enter a term in the search box.
Request a Consultation
To schedule a consultation with an oncologist at Dana-Farber/Brigham and Women's Cancer Center, please call one of our experienced appointment coordinators.
